Search

Your search keyword '"Li, Hongle"' showing total 153 results
Start Over Author "Li, Hongle"
153 results on '"Li, Hongle"'

1. The Optimized path for the public transportation of Incheon in South Korea

Author

faradunbeh, Soroor Malekmohammadi, Li, Hongle, Kang, Mangkyu, and Iim, Choongjae

Subjects
Physics - Physics and Society, Computer Science - Artificial Intelligence
Abstract

Path-finding is one of the most popular subjects in the field of computer science. Pathfinding strategies determine a path from a given coordinate to another. The focus of this paper is on finding the optimal path for the bus transportation system based on passenger demand. This study is based on bus stations in Incheon, South Korea, and we show that our modified A* algorithm performs better than other basic pathfinding algorithms such as the Genetic and Dijkstra. Our proposed approach can find the shortest path in real-time even for large amounts of data(points)., Comment: 5 pages, 4 figures, 2 tables, presented at Proc. of the Interdisciplinary Conference on Mechanics, Computers and Electrics (ICMECE 2022) 6-7 October 2022, Barcelona, Spain

Published
2023

2. An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an [HLA-DP5.sup.+] nasopharyngeal cancer mouse model

Author

Wang, Chenwei, Chen, Jiewen, Li, Jingyao, Xu, Zhihong, Huang, Lihong, Zhao, Qian, Chen, Lei, Liang, Xiaolong, Hu, Hai, Li, Gang, Xiong, Chengjie, Wu, Bin, You, Hua, Du, Danyi, Wang, Xiaoling, Li, Hongle, Wang, Zibing, and Chen, Lin

Subjects
T cells -- Growth, Nasopharyngeal cancer -- Drug therapy, Mass spectrometry -- Health aspects -- Analysis, Immunotherapy -- Analysis -- Health aspects, Antigens -- Growth, Cancer -- Care and treatment -- Drug therapy, Peptides -- Analysis -- Health aspects -- Growth, Company growth, Health care industry
Abstract

Adoptive transfer of T cell receptor-engineered T cells (TCR-T) is a promising strategy for immunotherapy against solid tumors. However, the potential of [CD4.sup.+] T cells in mediating tumor regression has been neglected. Nasopharyngeal cancer is consistently associated with EBV. Here, to evaluate the therapeutic potential of CD4 TCR-T in nasopharyngeal cancer, we screened for CD4 TCRs recognizing EBV nuclear antigen 1 (EBNA1) presented by HLA-DP5. Using mass spectrometry, we identified [EBNA1.sub.567-581], a peptide naturally processed and presented by HLA-DP5. We isolated TCR135, a CD4 TCR with high functional avidity, that can function in both [CD4.sup.+] and [CD8.sup.+] T cells and recognizes HLA-DP5-restricted [EBNA1.sub.567-581]. TCR135-transduced T cells functioned in two ways: directly killing [HLA-DP5.sup.+][EBNA1.sup.+] tumor cells after recognizing EBNA1 presented by tumor cells and indirectly killing HLA-DP5-negative tumor cells after recognizing EBNA1 presented by antigen- presenting cells. TCR135-transduced T cells preferentially infiltrated into the tumor microenvironment and significantly inhibited tumor growth in xenograft nasopharyngeal tumor models. Additionally, we found that 62% of nasopharyngeal cancer patients showed 50%-100% expression of HLA-DP on tumor cells, indicating that nasopharyngeal cancer is well suited for CD4 TCR-T therapy. These findings suggest that TCR135 may provide a new strategy for EBV-related nasopharyngeal cancer immunotherapy in [HLA-DP5.sup.+] patients., Introduction Recent advances in immunotherapy have shown promising results in the treatment of solid tumors. Adoptive transfer of T cell receptor- engineered (TCR-engineered) T cells (TCR-T) is a promising approach [...]

Published
2024
Full Text
View/download PDF

14. METTL1-mediated tRNA m7G methylation and translational dysfunction restricts breast cancer tumorigenesis by fueling cell cycle blockade.

Author

Du, Dan, Zhou, Mingxia, Ju, Chenxi, Yin, Jie, Wang, Chang, Xu, Xinyu, Yang, Yunqing, Li, Yun, Cui, Le, Wang, Zhengyang, Lei, Yuqing, Li, Hongle, He, Fucheng, and He, Jing

Subjects
TRANSFER RNA, FUEL cycle, CELL cycle, RNA modification & restriction, BREAST cancer, CYCLIN-dependent kinases, CANCER cell growth
Abstract

Background: RNA modifications of transfer RNAs (tRNAs) are critical for tRNA function. Growing evidence has revealed that tRNA modifications are related to various disease processes, including malignant tumors. However, the biological functions of methyltransferase-like 1 (METTL1)-regulated m7G tRNA modifications in breast cancer (BC) remain largely obscure. Methods: The biological role of METTL1 in BC progression were examined by cellular loss- and gain-of-function tests and xenograft models both in vitro and in vivo. To investigate the change of m7G tRNA modification and mRNA translation efficiency in BC, m7G-methylated tRNA immunoprecipitation sequencing (m7G tRNA MeRIP-seq), Ribosome profiling sequencing (Ribo-seq), and polysome-associated mRNA sequencing were performed. Rescue assays were conducted to decipher the underlying molecular mechanisms. Results: The tRNA m7G methyltransferase complex components METTL1 and WD repeat domain 4 (WDR4) were down-regulated in BC tissues at both the mRNA and protein levels. Functionally, METTL1 inhibited BC cell proliferation, and cell cycle progression, relying on its enzymatic activity. Mechanistically, METTL1 increased m7G levels of 19 tRNAs to modulate the translation of growth arrest and DNA damage 45 alpha (GADD45A) and retinoblastoma protein 1 (RB1) in a codon-dependent manner associated with m7G. Furthermore, in vivo experiments showed that overexpression of METTL1 enhanced the anti-tumor effectiveness of abemaciclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor. Conclusion: Our study uncovered the crucial tumor-suppressive role of METTL1-mediated tRNA m7G modification in BC by promoting the translation of GADD45A and RB1 mRNAs, selectively blocking the G2/M phase of the cell cycle. These findings also provided a promising strategy for improving the therapeutic benefits of CDK4/6 inhibitors in the treatment of BC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Figure S1 from T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes

Author

Li, Tiepeng, primary, Zhao, Lingdi, primary, Yang, Yonghao, primary, Wang, Yao, primary, Zhang, Yong, primary, Guo, Jindong, primary, Chen, Guangyu, primary, Qin, Peng, primary, Xu, Benling, primary, Ma, Baozhen, primary, Zhang, Fang, primary, Shang, Yiman, primary, Li, Qingjun, primary, Zhang, Kai, primary, Yuan, Dongfeng, primary, Feng, Chaojie, primary, Ma, Yan, primary, Liu, Zhiyong, primary, Tian, Zhichao, primary, Li, Hongle, primary, Wang, Shengdian, primary, and Gao, Quanli, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table S1 from T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes

Author

Li, Tiepeng, primary, Zhao, Lingdi, primary, Yang, Yonghao, primary, Wang, Yao, primary, Zhang, Yong, primary, Guo, Jindong, primary, Chen, Guangyu, primary, Qin, Peng, primary, Xu, Benling, primary, Ma, Baozhen, primary, Zhang, Fang, primary, Shang, Yiman, primary, Li, Qingjun, primary, Zhang, Kai, primary, Yuan, Dongfeng, primary, Feng, Chaojie, primary, Ma, Yan, primary, Liu, Zhiyong, primary, Tian, Zhichao, primary, Li, Hongle, primary, Wang, Shengdian, primary, and Gao, Quanli, primary

Published
2023
Full Text
View/download PDF

23. A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer

Author

Li, Sen, primary, Li, Ke, additional, Tian, Fei, additional, Li, Hongle, additional, Xia, Qingxin, additional, Li, Tiepeng, additional, Dong, Bing, additional, Li, Danyang, additional, Yu, Juan, additional, Zhang, Junli, additional, Wang, Li, additional, Zhang, Chengjuan, additional, Xu, Shuning, additional, Zhao, Yuzhou, additional, and Liu, Ying, additional

Published
2023
Full Text
View/download PDF

24. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers

Author

Li, Jun, primary, Wei, Bing, additional, Feng, Junnan, additional, Wu, Xinxin, additional, Chang, Yuxi, additional, Wang, Yi, additional, Yang, Xiuli, additional, Zhang, Haiyan, additional, Han, Sile, additional, Zhang, Cuiyun, additional, Zheng, Jiawen, additional, Groen, Harry J. M., additional, van den Berg, Anke, additional, Ma, Jie, additional, Li, Hongle, additional, and Guo, Yongjun, additional

Published
2022
Full Text
View/download PDF

25. Additional file 1 of IGF2BP2-induced circRUNX1 facilitates the growth and metastasis of esophageal squamous cell carcinoma through miR-449b-5p/FOXP3 axis

Author

Wang, Chang, Zhou, Mingxia, Zhu, Peiyu, Ju, Chenxi, Sheng, Jinxiu, Du, Dan, Wan, Junhu, Yin, Huiqing, Xing, Yurong, Li, Hongle, He, Jing, and He, Fucheng

Abstract

Additional file 1: Figure S1. High expression of circRUNX1 is related to advanced TNM stage and differentiation grade. Figure S2. CircRUNX1 overexpression promotes ESCC progression. Figure S3. FOXP3 is a downstream target of circRUNX1. Figure S4. FOXP3 knocking down inhibites ESCC cell proliferation and metastasis. Figure S5. CircRUNX1 facilitates ESCC cell progression by regulating FOXP3 in vitro. Figure S6. CircRUNX1 functions as a miR-449b-5p sponge in ESCC cells. Figure S7. The cancer-inhibiting effect of miR-449b-5p in ESCC cells can be reversed by FOXP3. Figure S8. Relative expression of seven candidate circRUNX1 binding proteins in ESCC tissues was predicted from GEPIA. Figure S9. Depletion of circRUNX1 rescues the promotive effect of IGF2BP2 overexpression on malignant behaviors in ESCC cells. Table S1. Sequences of siRNA and shRNA used in this study. Table S2. Primers used in this study. Table S3. Information of top 8 circRNAs in ESCC tissues. Table S4. The correlation between circRUNX1 and ESCC clinicopathological features. Table S5. The correlation between IGF2BP2 and ESCC clinicopathological features.

Published
2023
Full Text
View/download PDF

27. Profiling of Driver Mutations Identified Rare Compound Mutations Sensitive to Second-generation EGFR-TKI in Lung Adenocarcinoma Patients

Author

Li, Jun, primary, Zhang, Cuiyun, additional, Guan, Yuping, additional, Zheng, Jiawen, additional, Feng, Junnan, additional, Han, Sile, additional, Ma, Ruijuan, additional, Ren, Pengfei, additional, Li, Shasha, additional, Li, Yi, additional, Groen, Harry J. M., additional, Kok, Klaas, additional, Berg, Anke van den, additional, Wei, Bing, additional, Ma, Jie, additional, Guo, Yongjun, additional, and Li, Hongle, additional

Published
2022
Full Text
View/download PDF

28. Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients

Author

Yuan, Shumin, primary, Peng, Ling, additional, Liu, Yuqing, additional, Till, Brian G., additional, Yan, Xiang, additional, Zhang, Jie, additional, Zhu, Liping, additional, Wang, Huijuan, additional, Zhang, Shaokai, additional, Li, Hongle, additional, Gao, Quanli, additional, and Wang, Zibing, additional

Published
2022
Full Text
View/download PDF

30. Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies

Author

Huang, Hao, primary, Peng, Ling, additional, Zhang, Bicheng, additional, Till, Brian G., additional, Yang, Yonghao, additional, Zhang, Xiaojie, additional, Zhao, Lingdi, additional, Fu, Xiaomin, additional, Li, Tiepeng, additional, Han, Lu, additional, Qin, Peng, additional, Chen, Lin, additional, Yan, Xiang, additional, Liu, Yang, additional, Wang, Wenkang, additional, Ye, Zhenlong, additional, Li, Hongle, additional, Gao, Quanli, additional, and Wang, Zibing, additional

Published
2022
Full Text
View/download PDF

31. Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model

Author

Wang, Jianzheng, primary, Huang, Jinxi, additional, Wang, Hui, additional, Yang, Wei, additional, Bai, Qiwen, additional, Yao, Zhentao, additional, Li, Qingli, additional, Lv, Huifang, additional, Chen, Beibei, additional, Nie, Caiyun, additional, Xu, Weifeng, additional, Tu, Shuiping, additional, Li, Hongle, additional, and Chen, Xiaobing, additional

Published
2022
Full Text
View/download PDF

35. A High Interferon Gamma Signature of CD8 + T Cells Predicts Response to Neoadjuvant Immunotherapy Plus Chemotherapy in Gastric Cancer

Author

Li, Sen, primary, Li, Ke, additional, Tian, Fei, additional, Li, Hongle, additional, Xia, Qingxin, additional, Li, Tiepeng, additional, Dong, Bing, additional, Li, Danyang, additional, Yu, Juan, additional, Zhang, Junli, additional, Wang, Li, additional, Zhang, Chengjuan, additional, Xu, Shuning, additional, Zhao, Yuzhou, additional, and Liu, Ying, additional

Published
2022
Full Text
View/download PDF

38. Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety.

Author

Liu, Ying, primary, Han, Guangsen, additional, Li, Hongle, additional, Zhao, Yuzhou, additional, Li, Zhi, additional, Zhuang, Jing, additional, Wang, Gangcheng, additional, Li, Baodong, additional, Wang, Jinbang, additional, Li, Zhimeng, additional, Xia, Qingxin, additional, Zhang, Chengjuan, additional, Yu, Juan, additional, Li, Ke, additional, Xu, Shuning, additional, Qiao, Lei, additional, Kuang, Gaizhen, additional, and Li, Danyang, additional

Published
2021
Full Text
View/download PDF

39. Association of genomic characterization with clinical benefits of anti-PD-1 antibody combined with FOLFOX as neoadjuvant therapy on locally advanced gastric or gastroesophageal junction adenocarcinoma.

Author

Liu, Ying, primary, Han, Guangsen, additional, Li, Hongle, additional, Zhao, Yuzhou, additional, Li, Zhi, additional, Liu, Zhentian, additional, Zhuang, Jing, additional, Wang, Gangcheng, additional, Li, Baodong, additional, Wang, Jinbang, additional, Li, Zhimeng, additional, Xia, Qingxin, additional, Zhang, Chengjuan, additional, Yu, Juan, additional, Gao, Xuan, additional, Li, Ke, additional, Xu, Shuning, additional, Qiao, Lei, additional, Kuang, Gaizhen, additional, and Li, Danyang, additional

Published
2021
Full Text
View/download PDF

43. T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes

Author

Li, Tiepeng, primary, Zhao, Lingdi, additional, Yang, Yonghao, additional, Wang, Yao, additional, Zhang, Yong, additional, Guo, Jindong, additional, Chen, Guangyu, additional, Qin, Peng, additional, Xu, Benling, additional, Ma, Baozhen, additional, Zhang, Fang, additional, Shang, Yiman, additional, Li, Qingjun, additional, Zhang, Kai, additional, Yuan, Dongfeng, additional, Feng, Chaojie, additional, Ma, Yan, additional, Liu, Zhiyong, additional, Tian, Zhichao, additional, Li, Hongle, additional, Wang, Shengdian, additional, and Gao, Quanli, additional

Published
2021
Full Text
View/download PDF

50. Characterization of Synonymous BRCA1 :c.132C>T as a Pathogenic Variant.

Author

Li, Jun, Wang, Ping, Zhang, Cuiyun, Han, Sile, Xiao, Han, Liu, Zhiyuan, Wang, Xiaoyan, Liu, Weiling, Wei, Bing, Ma, Jie, Li, Hongle, and Guo, Yongjun

Subjects
OVARIAN cancer, PATIENTS' families, BRCA genes, RNA analysis, GENE expression, FAMILY history (Medicine)
Abstract

Breast cancer gene 1 (BRCA1) and BRCA2 are tumor suppressors involved in DNA damage response and repair. Carriers of germline pathogenic or likely pathogenic variants in BRCA1 or BRCA2 have significantly increased lifetime risks of breast cancer, ovarian cancer, and other cancer types; this phenomenon is known as hereditary breast and ovarian cancer (HBOC) syndrome. Accurate interpretation of BRCA1 and BRCA2 variants is important not only for disease management in patients, but also for determining preventative measures for their families. BRCA1 :c.132C>T (p.Cys44=) is a synonymous variant recorded in the ClinVar database with "conflicting interpretations of its pathogenicity". Here, we report our clinical tests in which we identified this variant in two unrelated patients, both of whom developed breast cancer at an early age with ovarian presentation a few years later and had a family history of relevant cancers. Minigene assay showed that this change caused a four-nucleotide loss at the end of exon 3, resulting in a truncated p.Cys44Tyrfs*5 protein. Reverse transcription-polymerase chain reaction identified two fragments (123 and 119 bp) using RNA isolated from patient blood samples, in consistency with the results of the minigene assay. Collectively, we classified BRCA1 :c.132C>T (p.Cys44=) as a pathogenic variant, as evidenced by functional studies, RNA analysis, and the patients' family histories. By analyzing variants recorded in the BRCA Exchange database, we found synonymous changes at the ends of exons could potentially influence splicing; meanwhile, current in silico tools could not predict splicing changes efficiently if the variants were in the middle of an exon, or in the deep intron region. Future studies should attempt to identify variants that influence gene expression and post-transcription modifications to improve our understanding of BRCA1 and BRCA2 , as well as their related cancers. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results